McElhenny Sheffield Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$779K Buy
3,094
+287
+10% +$61.7K 0.19% 24
2026
Q1
$610K Buy
2,807
+158
+6% +$35K 0.15% 28
2025
Q4
$605K Buy
2,649
+71
+3% +$16.2K 0.15% 29
2025
Q3
$597K Buy
2,578
+315
+14% +$64.1K 0.14% 39
2025
Q2
$420K Hold
2,263
0.11% 66
2025
Q1
$474K Sell
2,263
-6
-0.3% -$1.17K 0.18% 54
2024
Q4
$403K Buy
2,269
+17
+0.8% +$3.13K 0.14% 69
2024
Q3
$445K Buy
2,252
+18
+0.8% +$3.36K 0.15% 66
2024
Q2
$380K Hold
2,234
0.13% 66
2024
Q1
$395K Sell
2,234
-2
-0.1% -$345 0.14% 67
2023
Q4
$351K Hold
2,236
0.14% 65
2023
Q3
$333K Hold
2,236
0.17% 66
2023
Q2
$301K Sell
2,236
-6,777
-75% -$994K 0.13% 70
2023
Q1
$1.44M Sell
9,013
-1,344
-13% -$205K 0.76% 19
2022
Q4
$1.67M Sell
10,357
-6,737
-39% -$1.03M 0.77% 15
2022
Q3
$2.29M Buy
17,094
+33
+0.2% +$4.74K 1.75% 8
2022
Q2
$2.61M Buy
17,061
+1,439
+9% +$220K 1.22% 9
2022
Q1
$2.53M Sell
15,622
-555
-3% -$80.6K 0.88% 12
2021
Q4
$2.19M Buy
16,177
+280
+2% +$33.1K 0.82% 14
2021
Q3
$1.72M Buy
+15,897
New +$1.82M 0.78% 13

Other funds holding ABBV

McElhenny Sheffield Capital Management's ABBV Position: Q2 2026 in Review

McElhenny Sheffield Capital Management increased its AbbVie (ABBV) stake by 10% in Q2 2026, buying an estimated $61.7K and bringing the position to 3,094 shares worth $779K. The position accounts for 0.19% of the portfolio, ranked #24.

McElhenny Sheffield Capital Management first reported a position in ABBV in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.61M in Q2 2022. 1,681 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • McElhenny Sheffield Capital Management held 3,094 shares of AbbVie worth $779K as of Q2 2026.
  • McElhenny Sheffield Capital Management bought 287 AbbVie shares in Q2 2026, an estimated $61.7K.
  • AbbVie made up 0.19% of McElhenny Sheffield Capital Management's portfolio in Q2 2026, its #24 holding.
  • McElhenny Sheffield Capital Management first reported a position in AbbVie in Q3 2021 and has held it in 20 quarters since.
  • McElhenny Sheffield Capital Management's AbbVie position peaked at $2.61M in Q2 2022.
  • 1,681 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on McElhenny Sheffield Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.